PRODUCTS & SERVICES
Custom Oligonucleotides Services
We are deligted to announce that our company, was selected as one of 75 companies, in a competition of 1,852 projects from all over Europe, to win a prestigious EIC Accelerator grant. Therefore, we became the first Slovak company in history to be awarded an EIC Accelerator by the European Innovation Council (EIC) in the full amount of 3 million EUR, of which MultiplexDX will provide a half million EUR from its own resources.
“I'm incredibly proud of our entire team. Our success in the competition of nearly 2,000 innovative European projects, assessed by an international commission, confirms that our research meets the requirements for global R&D projects,”
says Pavol Čekan, co-founder and CEO of MultiplexDX.
The expert committee supported the Multiplex8+ project for its contribution to increasing the accuracy of diagnostics for breast cancer, which is one of the most widespread types of cancer. Currently, about 30 - 50% of breast cancers are misdiagnosed and the goal of Multiplex8+ is to increase the accuracy of breast cancer diagnostics from today's 50-70% to 98%.
The EIC Accelerator will support a large-scale retrospective clinical validation of Multiplex8+ on 4,000 archival tissue samples from Slovakia, Austria, Czech Republic and Iceland. If successful, the diagnostic test could enter the clinical practice as early as 2023.
"We believe that after verification in preclinical tests, Multiplex8+ will help cancer patients here in Slovakia, but of course we are counting on activities focused on the global healthcare segment,"
says Peter Kilian, COO of MultiplexDX.
“Better visual diagnostics and cross-validation with Multiplex8+ gene tests provide superior results. The accuracy of our diagnostics, reaching up to 98%, will provide oncologists with more accurate information about malignant tissue and allow better personalized treatment plans,”
explains P. Čekan, who is developing the unique diagnostics.
The EIC Accelerator (previously know as SME Instrument) is part of the European Innovation Council (EIC) pilot that supports high-risk, high-potential small and medium-sized enterprises and innovators to help them develop and bring onto the market new innovative products, services and business models that could drive economic growth.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.